Kirin-Amgen, Inc. and Others v. Hoechst Marion Roussel Limited and Others
United Kingdom House of Lords
[2004] UKHL 46
- Written by Craig Conway, LLM
Facts
Kirin-Amgen, Inc. (“Amgen”) (plaintiff) obtained a patent for a process of producing erythropoietin (“EPO”) using recombinant DNA technology. Hoechst Marion Roussel Limited, Transkaryotic Therapies Inc., and others (collectively “TKT”) (defendant) developed a similar process using the same technology. Amgen brought suit against TKT for infringement. At the trial court, the judge construed the claim terms in a “literal” manner and then addressed the Protocol questions. The judge concluded that the TKT’s process did not infringe Amgen’s patent. The Court of Appeal affirmed and Amgen appealed.
Rule of Law
Issue
Holding and Reasoning (Hoffmann, L.)
What to do next…
Here's why 802,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.